Abstract
In April 2000, a 54-year-old woman underwent surgery for ovarian serous cell carcinoma (stage IIb). After initial treatment, the patient underwent a physical examination, ultrasound examination and measurement of serum CA-125 levels every month. Although neither diagnostic imaging (ultrasound and computed tomography) nor physical examination showed any evidence of recurrence, the CA-125 level rose slowly and continuously within the normal range. In March 2001, an increased accumulation of18F-fluorodeoxyglucose (FDG) in the pelvic cavity was seen on a positron emission tomography (PET) scan obtained 2 weeks before a relapse of a malignant lesion was diagnosed by gadolinium-enhanced MRI (Gd-MRI). It is reasonable to suppose that FDG-PET is clinically useful for detecting an early, small region of relapsed ovarian cancer. Moreover, FDG-PET may be helpful for determining whether a patient who has a continuous rising CA-125 level within the normal range should be treated in the absence of relapse regions detected by conventional methods.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In:Principles and Practice of Gynecologic Oncology, 3rd ed. William JH, Carlos AP, Robert CY (eds), Philadelphia; Lippincott Williams & Wilkins, 1999: 841–918.
Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.Gynecol Oncol 2001; 81: 237–241.
Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer.Br J Cancer 2000; 82: 1535–1538.
Kitagawa Y, Sadato N, Azuma H, Ogasawara T, Yoshida M, Ishii Y, et al. FDG PET to evaluate combined intraarterial chemotherapy and radiotherapy of head and neck neoplasms.I Nucl Med 1999; 40: 1132–1137.
Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32: 623–645.
Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.J Comput Assist Tomogr 1993; 17: 626–632.
Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group.Radiology 1999; 212: 19–27.
Hamm B, Kubik-Huch RA, Fleige BX. MR imaging and CT of the female pelvis: radiologic-pathologic correlation.Eur Radiol 1999; 3: 3–15.
Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.Am J Roentgenol 2001; 176: 1449–1454.
Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of18F-fluoro-deoxyglucose positron emission tomography (18F-FDG-PET) in diagnosis of ovarian cancer.Int J Gynecol Cancer 1999; 9: 117–122.
Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.J Reprod Med 1999; 44: 775–778.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kurokawa, T., Yoshida, Y., Kawahara, K. et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann Nucl Med 16, 491–493 (2002). https://doi.org/10.1007/BF02988649
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02988649